CN103417694A - Traditional Chinese medicine used for treating diabetes - Google Patents
Traditional Chinese medicine used for treating diabetes Download PDFInfo
- Publication number
- CN103417694A CN103417694A CN2012101601711A CN201210160171A CN103417694A CN 103417694 A CN103417694 A CN 103417694A CN 2012101601711 A CN2012101601711 A CN 2012101601711A CN 201210160171 A CN201210160171 A CN 201210160171A CN 103417694 A CN103417694 A CN 103417694A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- diabetes
- glucose
- traditional chinese
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine used for treating diabetes. Raw materials of the traditional Chinese medicine comprise radix astragali, coptidis rhizome, clausena lansium and rheum officinale. The raw materials are prepared into tablets or other preparation forms according to a ratio. The traditional Chinese medicine has a reasonable formula, a unique preparation method, and a good therapeutic effect for the diabetes.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of Chinese medicine for the treatment of diabetes, particularly relate to a kind of Chinese medicine of take the treatment diabetes that vegetable Chinese herbal medicine makes as raw material.
Background technology
Diabetes are the commonly encountered diseases that caused by the h and E factor interaction, the symptom of diabetes can be divided into two large classes: a large class is the performance relevant with metabolism disorder, especially relevant with hyperglycemia " three-many-one-little ", be more common in type 1 diabetes, type 2 diabetes mellitus is often not fairly obvious or part performance only arranged; Another large class is the performance of various diabetic complications.
1. polyuria is because blood glucose is too high, surpasses renal glucose threshold (8.89 ~ 10.0mmol/L), and the glucose leached through glomerule can not be fully by reabsorption, form osmotic diuresis, blood glucose is higher, and the glucose in urine excretion is more, and the urine amount is more, 24h urine amount can reach 5000 ~ 10000mL, but old people and the person that has the kidney disease, renal glucose threshold increases, the glucose in urine acatharsia, when the light moderate of blood glucose increases, polyuria can be not obvious.
2. polydipsia obviously increases plasma osmotic pressure mainly due to hyperglycemia, polyuria in addition, and loss of moist is too much, dehydration in cell occurs, increase the weight of hyperglycemia, plasma osmotic pressure is further obviously raise, stimulate thirst center, cause thirsty and polydipsia, polydipsia further increases the weight of polyuria.
3. the mechanism of polyphagia polyphagia is not fully aware of, most scholar's tendencies are due to glucose utilization rate (in the arteriovenous blood of turnover histiocyte front and back, concentration of glucose is poor) reduces, concentration of glucose is poor in arteriovenous blood on an empty stomach dwindles for the normal person, stimulates feeding center, produces hunger sensation; The rear blood sugar increasing of ingesting, the poor increasing of arteriovenous blood level, feeding center is suppressed, the satiety center excitement, ingest and require to disappear, yet the diabetes patient is because insulin definitely or relatively lacks or organize insulin insensitivity, and the tissue picked-up utilizes the glucose ability to descend, although blood glucose is in high level, but in arteriovenous blood, the concentration difference of glucose is very little, histiocyte is in fact in " starvation ", thereby the stimulation feeding center causes hunger and polyphagia; In addition, body can not take full advantage of glucose, and a large amount of glucoses are excretion from urine, so body is in fact in the semistarvation state, and energy deficiency also causes bulimia.
4. although weight loss diabetics appetite and appetite are normal, even increase, but weight loss, mainly because insulin definitely or relatively lacks or insulin resistant, body can not take full advantage of the glucose produce power, causing fat and protein to decompose strengthens, consume too much, be negative nitrogen balance, body weight descends gradually, and even occur becoming thin, once diabetes are through reasonably treatment, after obtaining good control, weight loss can be controlled, go up even to some extent, as diabetics body weight continuous decrease or obviously become thin in therapeutic process, prompting is may Metabolism control not good or merge other Chronic consumptionss.
5. weak is also common in diabetics, and because glucose can not be by complete oxidation, human body can not take full advantage of glucose and effectively give off energy, organize dehydration simultaneously, electrolyte imbalance and negative nitrogen balance etc., thereby feel malaise, lethargy.
6. when the many diabeticss of visual deterioration are gone to a doctor in early days, main suit's visual deterioration or fuzzy, this mainly may cause crystalloid osmotic pressure to change with hyperglycemia, cause due to the variation of crystal diopter, early stage general many function of dominants sexually revise, once blood glucose obtains good control, it is normal that vision can comparatively fast be recovered.
7. the complication diabetic complication is numerous, can be divided into acute complications and chronic complicating diseases, acute complications mainly comprises diabetic ketoacidosis (be more common in type 1 diabetes, type 2 diabetes mellitus stress also can occur under situation) and the high NKC (being more common in type 2 diabetes mellitus) that oozes of diabetes; Each histoorgan of chronic complicating diseases accumulation whole body, mainly comprise that trunk is (as cardiovascular, cerebrovascular, kidney blood vessel and extremity trunk), blood capillary (as diabetic nephropathy and diabetic renal papillary necrosis) and neuropathy (as autonomic nerve and somatic nerve etc.) etc.
At present, there is following problem in the domestic and international Drug therapy to diabetes: the biguanides side effect is large; Sulfonamides medicine infringement liver, kidney, and easy and sulfa drugs generation cross allergy.Therefore, developing the safe and effective Chinese medicine that is intended to treat diabetes is significant.
Summary of the invention
For the deficiencies in the prior art, the invention provides a kind of Chinese medicine preparation for the treatment of diabetes, its prescription flavour of a drug are few, evident in efficacy.
In order to reach the foregoing invention purpose, solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to onset diabetes mechanism, and the Chinese herbal medicine that screening has potential treatment diabetes, according to the theory of Chinese medical science prescription.
For this reason, technical solution of the present invention has been to provide a kind of Chinese medicine for the treatment of diabetes, it is characterized in that: it is made with the weight ratio of following component, and its component proportioning is:
The Radix Astragali 9 ~ 30
Rhizoma Coptidis 2 ~ 5
Cortex Phellodendri 3 ~ 12
Radix Et Rhizoma Rhei 5 ~ 15
A kind of optimum ratio for the treatment of the Chinese medicine of diabetes of the present invention is the raw material that contains following weight parts:
The Radix Astragali 15
Rhizoma Coptidis 3
Cortex Phellodendri 8
Radix Et Rhizoma Rhei 10
A kind of Chinese medicine for the treatment of diabetes of the present invention, is characterized in that said medicine is decocted with water to secondary, and 2 hours for the first time, 1 hour for the second time, decocting liquid filtered, filtrate merges, and is condensed into thick paste, adds appropriate starch, mixes granule processed, drying, tabletting, coating, obtain.
The following describes the effect of herbal raw material in the present invention:
The Radix Astragali: be the root of leguminous plant Radix Astagali Astragalus memeranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Radix Astragali A.membranaceus (Fisch.) Bge..Main product in the Inner Mongol, the ground such as Shanxi, Heilungkiang.Two seasons of spring and autumn excavate, and remove fibrous root and root head, dry, and section, give birth to and use or processed with honey use.Sweet in the mouth, slightly warm in nature.Return spleen, lung meridian.There is the spleen invigorating invigorating middle warmer, ascending up spleen-Qi and Yang, benefit is defended consolidating superficial resistance, diuresis, the effect of promoting pus discharge and tissue regeneration strengthening.
Rhizoma Coptidis: be the dry rhizome of ranunculaceae plant Rhizoma Coptidis Coptis chinensis Franch., Coptis deltoidea C.Y.Cheng et Hsiao C.deltoidea C.Y.Cheng et Hsiao or Coptis Teeta Wall C.teeta Wall..Above three kinds can be described as respectively " flavor connects ", " refined company ", " Coptis Teeta Wall ".Polyphyly cultivation, main product in Sichuan, Yunnan, Hubei.Excavate autumn, removes fibrous root and silt, drying.Give birth to or fry, stir-frying with ginger juice, wine are processed, Fructus Evodiae water is processed use.Bitter in the mouth, cold in nature.GUIXIN, spleen, stomach, gallbladder, large intestine channel.There is heat clearing and damp drying, the effect of eliminating fire and detoxication.
Cortex Phellodendri: be the dry bark of rutaceae wampee Phellodendron chinense Schneid. or Cortex Phellodendri P.amurense Rupr..The former practises title " Cortex Phellodendri ", and the latter practises title " Cortex Phellodendri ".The Cortex Phellodendri main product in Sichuan, the ground such as Guizhou, Hubei, Yunnan, the Cortex Phellodendri main product in Liaoning, the ground such as Jilin, Hebei.Strip bark after clear and bright, remove rough bark, dry pressing; Run through section or shredding.Give birth to or saline is processed, parch to black use.Bitter in the mouth, cold in nature.Return kidney, bladder, large intestine channel.Have heat clearing and damp drying, pathogenic fire purging is except steaming, the effect of detoxification sore treatment.
A kind of Chinese medicine for the treatment of diabetes of the present invention, upper on the basis of mentioned component, directly or again add suitable edible or pharmaceutic adjuvant, can make capsule, tablet, granule, oral liquid, powder etc.The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic etc.
The specific embodiment
Embodiment 1: the preparation of tablet
Take raw material in following ratio:
The Radix Astragali 750 Rhizoma Coptidis 150 Cortex Phellodendri 400 Radix Et Rhizoma Rhei 500
Said medicine is decocted with water to secondary, and 2 hours for the first time, 1 hour for the second time, decocting liquid filtered, and filtrate merges, and is condensed into thick paste, adds appropriate starch, mix, and granule processed, drying, be pressed into 1000, and coating, obtain.
Embodiment 2: the impact of Chinese medicine successive administration of the present invention on the type 2 diabetes mellitus rat blood sugar
Experimental technique: 100 of male and female half and half rats, adaptability was fed after 7 days, stayed 10 for Normal group, another 90 modelings.Sublingual vein injection STZ solution 30mg/kg(prepares with the citrate buffer solution of 0.1mol/L pH4.5 before use), select impaired glucose tolerance (IGT) after three weeks and feed that (normal feedstuff is with sucrose with high-calorie feed, refining Adeps Sus domestica, fresh hen eggs etc. mix, containing protein 15%-18%, and carbohydrate 51%-54%, fat 22%-25%, heat is 20.08kJ/g), continue 10 weeks, normal group is to normal feedstuff.STZ10 is after week in injection, detects fasting glucose (FGB), glucose tolerance (IGT), insulin and blood fat.Get there is IGT, rat that hyperglycemia and hyperlipidemia, insulin level increase is defined as the type 2 diabetes mellitus rat.Get 50 of type 2 diabetes mellitus rats, by the fasting glucose equilibrium, be divided into 5 groups, be respectively model control group, medicine of the present invention (300mg/kg, 150mg/kg, 75mg/kg) group, and insoral group (75mg/kg), and establish Normal group.Each group is used normal feedstuff instead and is fed.Model group and Normal group give the isometric(al) normal saline, all in the morning gavage once, continuous surrounding.After administration weekly, rat fasting 12 hours, eye socket is got blood, separation of serum, the hexokinase method is surveyed blood glucose.
Experimental result: Chinese medicine of the present invention has significance and falls hypoglycemic effect, in Table 1.
The variation of blood glucose after the continuous surrounding administration of table 1 Chinese medicine of the present invention
With model control group, compare
*P<0.05,
*P<0.01
Embodiment 3: the impact of Chinese medicine successive administration surrounding of the present invention on type 2 diabetes mellitus rat carbohydrate tolerance
Experimental technique: the modeling of type 2 diabetes mellitus rat and grouping are the same, after Chinese medicine of the present invention (method for making is with embodiment 1) successive administration surrounding, before the last administration, fasting is 12 hours, the eye socket posterior vein is got blood, separation of serum is surveyed blood glucose as 0 o'clock blood glucose, administration after 30 minutes respectively, with 2.5g/kg dosage gavage to glucose, within latter 30 minutes, 60 minutes, 120 minutes, get blood to sugar, hexokinase method is surveyed blood glucose.
Experimental result: after Chinese medicine successive administration surrounding of the present invention, its high, normal, basic dosage (300mg/kg, 150mg/kg, 75mg/kg) all obviously reduces the of short duration rising of blood glucose that the type 2 diabetes mellitus rat causes due to exogenous glucose, improves the sugared toleration of animal subject.The results are shown in Table 2.
The variation of carbohydrate tolerance after table 2 Chinese medicine administration of the present invention
With model control group, compare
*P<0.05,
*P<0.01.
Claims (2)
1. a Chinese medicine for the treatment of diabetes, it is characterized in that: it is made with the weight ratio of following component, and its component proportioning is: 9 ~ 30 parts of the Radixs Astragali, 2 ~ 5 parts of Rhizoma Coptidis, 3 ~ 12 parts of Cortex Phellodendris, 5 ~ 15 parts of Radix Et Rhizoma Rhei.
2. a kind of Chinese medicine for the treatment of diabetes according to claim 1, it is characterized in that: it is made with the weight ratio of following component, and its component proportioning is: 15 parts of the Radixs Astragali, 3 parts of Rhizoma Coptidis, 8 parts of Cortex Phellodendris, 10 parts of Radix Et Rhizoma Rhei.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101601711A CN103417694A (en) | 2012-05-23 | 2012-05-23 | Traditional Chinese medicine used for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101601711A CN103417694A (en) | 2012-05-23 | 2012-05-23 | Traditional Chinese medicine used for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103417694A true CN103417694A (en) | 2013-12-04 |
Family
ID=49643435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101601711A Pending CN103417694A (en) | 2012-05-23 | 2012-05-23 | Traditional Chinese medicine used for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417694A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334994A (en) * | 2017-07-12 | 2017-11-10 | 广州中医药大学 | A kind of pharmaceutical composition and preparation method thereof, application |
| CN111870623A (en) * | 2020-07-22 | 2020-11-03 | 黄英俊 | Lihuangyin (decoction of Lian Huang) |
| CN112603949A (en) * | 2021-01-12 | 2021-04-06 | 李天顺 | Chinese medicinal preparation for treating diabetes |
-
2012
- 2012-05-23 CN CN2012101601711A patent/CN103417694A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334994A (en) * | 2017-07-12 | 2017-11-10 | 广州中医药大学 | A kind of pharmaceutical composition and preparation method thereof, application |
| CN107334994B (en) * | 2017-07-12 | 2020-11-20 | 广州中医药大学 | Pharmaceutical composition and preparation method and application thereof |
| CN111870623A (en) * | 2020-07-22 | 2020-11-03 | 黄英俊 | Lihuangyin (decoction of Lian Huang) |
| CN112603949A (en) * | 2021-01-12 | 2021-04-06 | 李天顺 | Chinese medicinal preparation for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100420472C (en) | Diabetes treating medicine | |
| CN102302563B (en) | Chinese medicinal composition for treating chronic kidney failure and preparation method thereof | |
| CN103690783B (en) | Chinese medicine preparation being used for the treatment of diabetes and preparation method thereof | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN103040960A (en) | Traditional Chinese medicine formula for treating high blood pressure | |
| CN101947284A (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN105148077A (en) | Health preserving porridge with blood sugar decreasing effect | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN102973895B (en) | Traditional Chinese medicine combination for treating nervous vomiting | |
| CN102178788B (en) | Chinese medicinal composition for reducing transaminase and jaundice and preparation method thereof | |
| CN103417694A (en) | Traditional Chinese medicine used for treating diabetes | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN100388945C (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN101549045B (en) | Traditional Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN102114206B (en) | Powder capable of restoring function of pancreatic islet and preparation method thereof | |
| CN104013806A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| CN104288527B (en) | It is a kind of to be used to treat Chinese medicine composition of diabetes and preparation method and application | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN103463358A (en) | Traditional Chinese medicine compound preparation for treatment of diabetes and preparation method thereof | |
| CN113826882A (en) | Dietary nutrition supplement for preventing and treating diabetes and preparation process thereof | |
| CN105663439A (en) | Pharmaceutical composition for preventing and treating diabetes and preparation method thereof | |
| CN105381201A (en) | Preparation method for traditional Chinese medicine used for diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131204 |